Effects of ozone injection in treatment of women with mild and moderate carpal tunnel syndrome

Study of the effects of ozone injection in women with mild and moderate Carpal Tunnel Syndrome in physical medicine and rehabilitation clinic

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016040913442N9

Enrollment

Registered

2016-07-14

Start date

2016-06-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal Tunnel Syndrome. Carpal Tunnel Syndrome

Interventions

Intervention 1: Single injection of 4 ml of ozone with 5 cc syringe and prefabricated hand wrist splint in neutral position (0-5 extension) for CTS for 8 weeks. Intervention 2: Prefabricated hand wris

Treatment - Drugs

Treatment - Devices

Single injection of 4 ml of ozone with 5 cc syringe and prefabricated hand wrist splint in neutral position (0-5 extension) for CTS for 8 weeks

Prefabricated hand wrist splint in neutral position (0-5 extension) for CTS for 8 weeks

Eligibility

Sex/Gender

Female

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patient with mild and moderate CTS confirmed by the presence of one or more of the following standard electrophysiological criteria: 1- prolonged distal motor latency (DML) (abnormal =4.2 ms) of Median nerve and 2- prolonged antidromic distal sensory latency (DSL) to the third digit (abnormal >3.6 ms; age between 20 to 65 years old. Exclusion criteria: Pregnancy; Severe degree CTS; Background metabolic diseases such as: diabetes mellitus; hypothyroidism; rheumatoid arthritis; Previous history of corticosteroid injection in Carpal Tunnel Syndrome; Severe atrophy of tenar muscles; cervical radiculopathy or significant polyneuropathy; Unwillingness to participate in the present study; patient younger than 20 or older than 65 years old. G6PD

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: 0, 10 weeks, 6 months. Method of measurement: Visual Analog Scale, that is from 0-10 and zero (0) means that you did not have any pain and ten (10) means that you had the worst pain imaginable.;Functional Status. Timepoint: 0, 10 weeks, 6 months. Method of measurement: Bostone/levine Functional Status Scale Questionnare.;Symptome Severity (pain and paresthesia). Timepoint: 0,10 weeks, 6 months. Method of measurement: Bostone/levine Symptome Severity Scale Questionnare.;Distal Sensory Peak Latency (SNAP) of median nerve. Timepoint: 0,10 weeks, 6 months. Method of measurement: EDX Indexes.;Distal Motor Onset Latency (CMAP) of median nerve. Timepoint: 0,10 weeks, 6 months. Method of measurement: EDX indexes.	—

Measure

Time frame

Pain. Timepoint: 0, 10 weeks, 6 months. Method of measurement: Visual Analog Scale, that is from 0-10 and zero (0) means that you did not have any pain and ten (10) means that you had the worst pain imaginable.;Functional Status. Timepoint: 0, 10 weeks, 6 months. Method of measurement: Bostone/levine Functional Status Scale Questionnare.;Symptome Severity (pain and paresthesia). Timepoint: 0,10 weeks, 6 months. Method of measurement: Bostone/levine Symptome Severity Scale Questionnare.;Distal Sensory Peak Latency (SNAP) of median nerve. Timepoint: 0,10 weeks, 6 months. Method of measurement: EDX Indexes.;Distal Motor Onset Latency (CMAP) of median nerve. Timepoint: 0,10 weeks, 6 months. Method of measurement: EDX indexes.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadrasoul nezamabadi

Modarres hospital

mohammadrasoul@outlook.com+98 212207409

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 3, 2026